Los Altos, CA – According to filings with the U.S. Securities and Exchange Commission, Retrotope is raising $50,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Molinari played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Retrotope

Retrotope has created a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. The unique mechanism of Retrotope’s platform prevents cellular damage and recovers cellular function damaged by lipid peroxidation due to oxidative stress. Retrotope’s first product candidate, RT001, is being clinically tested in Friedreich’s ataxia (FA) and Infantile Neuroaxonal Dystrophy (INAD), both untreated fatal orphan diseases. Other stabilized lipid drugs based on Retrotope’s transformational platform technology have the potential to treat a wide variety of other mitochondrial myopathies and neurodegenerative diseases.

To learn more about Retrotope, visit http://www.retrotope.com/

Contact:
Robert Molinari, Chief Executive Officer
650-575-7551
robert@retrotope.com
https://www.linkedin.com/in/bob-molinari-28bb98/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved